Drugs / DFP-11207
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02171221 | Jun 2014 → Sep 2018 | cancer | Delta-Fly Pharma, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DFP-11207 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02171221 ↗ |
| Action | Inhibit | “a reversible DPD inhibitor and a potent inhibitor of OPRT” PMID 32377978 ↗ May 2020 |
| Route | Oral | “DFP-11207 was administered orally daily” PMID 32377978 ↗ May 2020 |